JPMorgan raised the firm’s price target on Inspire Medical (INSP) to $118 from $82 and keeps a Neutral rating on the shares. The firm updated the company’s model to reflect its increased reimbursement rates.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Oppenheimer upgrades Inspire Medical to Outperform on CMS blunder
- Inspire Medical upgraded to Outperform from Perform at Oppenheimer
- Inspire Medical price target raised to $165 from $135 at Piper Sandler
- Inspire Medical price target raised to $180 from $125 at Baird
- Teradyne upgraded, Circle Internet initiated: Wall Street’s top analyst calls